Atara Q2 net income $18.5M; workforce cut 20%; CCO departure; Bayer deal terminated; FDA supports tab-cel BLA path

Atara Biotherapeutics, Inc.

2022-Q2 EPS reported -$0.69 revenue$58,893,000

Net income $18.5M ($0.18/diluted) vs net loss $83.8M in Q2 2021; includes $50.2M gain on ATOM facility sale.
Workforce reduction of ~20% to reduce future annual cash burn by >20%; expects $6M severance charges; cash runway extended to Q1 2024.
Bayer termination agreement: Bayer pays $4.2M, returns rights to ATA2271/ATA3271; license and collab revenue $51.6M in Q2 from termination.
FDA recommended pathway to BLA for tab-cel without new trial; EC approval on track Q4 2022.
Kristin Yarema, SVP & CCO, to depart effective Nov 15, 2022; severance of 12 months base salary.

item 1.01 item 2.02 item 2.05 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kristin Yarema

Senior Vice President and Chief Commercial Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2022-11-15
Filed: August 8, 2022, 7:59 PM ET

the employment of Kristin Yarema, the Company’s Senior Vice President and Chief Commercial Officer, will terminate effective as of November 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kristin Yarema was terminated as Senior Vice President and Chief Commercial Officer at Atara Biotherapeutics, Inc..

Action: terminated
Role: Senior Vice President and Chief Commercial Officer

Exact text from the filing

the employment of Kristin Yarema, the Company’s Senior Vice President and Chief Commercial Officer, will terminate effective as of November 15, 2022.

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-015519

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.